Movement disorders:帕金森病的运动和认知代谢网络之间的关系

2022-08-30 Freeman MedSci原创

通过delta量化的PDRP优势,可以检测出PD患者的功能障碍从运动网络向认知网络的扩散

尽管特发性帕金森病(iPD)患者的症状表现和疾病进展各不相同,但基本的组织病理学变化和所涉及区域的时间顺序是相对定型的。iPD与两个不同的代谢网络有关,即PD相关模式(PDRP)和PD相关认知模式(PDCP),它们分别与该疾病的运动和认知表现有关。用[18F]-氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)进行的纵向成像研究表明,PDCP在运动发病后4至6年开始明显升高。因此,与PDCP相比,在同一病人身上测量PDRP时,预计PDRP会有优势的表达。

 

图1: 论文封面图

在这种情况下,PDRP的优势可以从Braak最初描述的iPD的组织病理学变化的区域顺序来理解。疾病相关网络的异常甚至可能早于运动症状的出现,这一点从特发性快速眼动睡眠行为障碍(iRBD)患者的PDRP升高可以看出,这是一种前驱形式的疾病。相反,在非典型帕金森综合征(APS)中,如多系统萎缩(MSA)和进行性核上性麻痹(PSP),PDRP不可能占优势,Braak的顺序并不适用。


在这项研究中,斯洛文尼亚UMC Ljubljana的Tomaz Rus 等评估了不同病程的iPD患者的多个样本的PDRP优势,这些患者在四个不同的部位进行了FDG-PET扫描。对于每个病人,他们测量了PDRP和PDCP的表达水平,并计算了这些数值的差异,这被称为delta。我们研究了横断面iPD样本中delta与疾病持续时间的关系以及随着时间的推移。

同样,将iPD患者的delta与iRBD19受试者以及与LRRK2-G2019S突变相关的PD基因型和与疾病进展缓慢和更快相关的GBA1变体患者的相应数值进行比较。所得数据与APS患者中获得的相应措施进行了比较。最后,作为原则性证明,使用静止状态fMRI(rs-fMRI)非侵入性地获得类似的结果,证明了delta更广泛的应用潜力。

图2:论文结果图


他们使用[18F]-氟脱氧葡萄糖正电子发射断层扫描和静息态fMRI来量化delta,并比较不同样本的测量结果;同样在纵向的病人样本中评估delta随时间的变化。最后,评估了iRBD前驱个体和gPD受试者的delta。

四个iPD样本中的每一个Delta都异常升高(P < 0.05),在有风险的iRBD组中也是如此(P < 0.05),其数值随时间的推移而增加(P < 0.001)。

PDRP的优势也存在于gPD中,与侵略性较弱的LRRK2-G2019S突变相比,GBA1变体患者的数值更高(P = 0.005)

这一趋势在非典型帕金森综合征患者中没有观察到,根据PDRP的表达和delta(曲线下面积=0.85;P < 0.0001),他们与iPD的区别很准确。

该研究的重要意义在于发现了:通过delta量化的PDRP优势,可以检测出PD患者的功能障碍从运动网络向认知网络的扩散。因此,Delta可能有助于鉴别诊断和跟踪个别患者的疾病进展。

 


原文出处:
Rus T, Schindlbeck KA, Tang CC, et al. Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson’s Disease. _Movement Disorders_. Published online August 23, 2022:mds.29188. doi:[10.1002/mds.29188](https://doi.org/10.1002/mds.29188)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
    2022-11-08 cmsvly
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
    2022-11-18 anminleiryan
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]

相关资讯

JAMA Netw Open:做好这两点,帕金森病患者全因死亡风险骤降65%!

 JAMA Netw Open:饮食和身体活动与帕金森病成人全因死亡率的关系

Movement disorders:血清MicroRNAs可预测孤立的快速眼动睡眠行为障碍和路易体疾病

仅特定的miRNA生物特征就有希望作为IRBD患者的进展生物标志物来预测PD和DLB的临床结果。

Movement disorders:大脑代谢与前驱和早期帕金森病中的多巴胺能失调有关

在前驱期和早期PD阶段,与多巴胺能神经支配有关的各个脑区的代谢反应的轨迹是不同的。

Movement disorders:湘雅医院:狗狗嗅一嗅,就能诊断帕金森病?

使用嗅探犬进行测试可能是一种有用的、无创的、快速的和具有成本效益的方法

Movement disorders:葡萄糖苷酶变体携带者和家族性帕金森病的性别频率差异

GBA PD总体上存在的男性性别优势在GBA变异的严重程度上并不一致,

JAMA子刊:高翔教授发现吃得对会运动,帕金森死亡率能降一半!

无论是健康饮食还是积极锻炼,都能充分保护帕金森患者的寿命。

拓展阅读

综述|重复经颅磁刺激治疗帕金森病言语障碍研究进展

rTMS在PD言语障碍的治疗中取得了良好的效果,但目前研究的数量较少,未来还需要更多大规模和大样本量的随机对照试验来进一步验证和支持其效果。

Lancet Neurol:帕金森病新分类模型

该模型被称为SynNeurGe(发音为“synergy”),旨在捕捉帕金森病的异质性,并帮助研究该疾病的潜在生物学。

疑难探究:当帕金森病遇到OH如何与MSA-P 鉴别?

MSA患者的认知缺陷仍未得到很好的描述,OH是否会像PD一样增加MSA患者未来痴呆的风险仍有待评估。

帕金森病:认知障碍From PD-MCI to PDD

帕金森病的认知能力下降与胆碱能系统退化有关,这可以使用基底前脑体积的结构性MRI标记物和皮质胆碱能活性的PET测量在体内进行评估。

帕金森病:睡眠障碍与昼夜节律

帕金森病是一种进行性神经退行性疾病,具有运动和非运动症状,包括睡眠功能障碍。非运动症状对生活质量有负面影响,并且通常比运动症状更令人烦恼。

European Radiology:使用多模态PET/MRI放射组学识别帕金森病和多系统萎缩

放射组学是指从医学影像中高通量提取丰富的影像信息,以辅助医生做出最准确的诊断。现阶段,放射组学已广泛应用于肿瘤学研究,如肿瘤的诊断、分级、疗效评估、预后预测等。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10